The AvertD test is intended to be used prior to first exposure to oral opioids in patients considered for a 4-30 day prescription for acute pain.
The AvertD test is intended to be used prior to first exposure to oral opioids in patients considered for a 4-30 day prescription for acute pain.
As opioid utilization decreases, other pharmacy trends bear watching.
These funds will help states and communities respond more quickly, effectively, and equitably to prevent overdose death and injury.
According to JAMA, only 22% of OUD patients received medication-assisted therapy.
RiVive will soon be available without a prescription for the treatment of known or suspected opioid overdose.
A new buprenorphine injection will be available for weekly or monthly dosages, administered by providers.
A new report from the CWCI highlights trends in dermatologicals, opioids, and antidepressants.
Changes to boxed warnings, indications and usage, dosage and administration, and more.
New reports from the Journal of the American Medical Association and Health Economics.
This vaccine blocks fentanyl from entering the brain and triggering euphoric effect.
